Romiplostim resistance in secondary failure of platelet recovery

David L. Deremer, Katerina Katsanevas, Amber Bradley, Farrukh T. Awan

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Romiplostim, a thrombopoietin mimetic, is FDA approved for the treatment of thrombocytopenia in patients with refractory immune thrombocytopenia. Given the success of thrombopoietin agonists in the treatment of immune thrombocytopenia, data in other clinical settings are emerging. In the bone marrow transplant setting, secondary failure of platelet recovery and persistent thrombocytopenia are associated with increased mortality. In this case, romiplostim was attempted in a chronic lymphocytic leukemia patient who underwent a matched, unrelated donor, non-myeloablative stem cell transplant. This patient experienced profound thrombocytopenia despite dose escalation. Anti-thrombopoietin or anti-romiplostim antibodies were not detected by specific assays. Furthermore, the patient remains in disease remission with full chimerism. This case demonstrates that heavily pre-treated patients with limited bone marrow reserve may not respond to thrombopoietin agonists.

Original languageEnglish (US)
Pages (from-to)369-372
Number of pages4
JournalJournal of Oncology Pharmacy Practice
Volume19
Issue number4
DOIs
StatePublished - Dec 1 2013
Externally publishedYes

Fingerprint

Thrombopoietin
Blood Platelets
Thrombocytopenia
Idiopathic Thrombocytopenic Purpura
Bone Marrow
Transplants
Unrelated Donors
Chimerism
B-Cell Chronic Lymphocytic Leukemia
Anti-Idiotypic Antibodies
Stem Cells
romiplostim
Mortality
Therapeutics

Keywords

  • allogeneic stem cell transplant
  • chronic lymphocytic leukemia
  • romiplostim
  • Secondary failure of platelet recovery

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Romiplostim resistance in secondary failure of platelet recovery. / Deremer, David L.; Katsanevas, Katerina; Bradley, Amber; Awan, Farrukh T.

In: Journal of Oncology Pharmacy Practice, Vol. 19, No. 4, 01.12.2013, p. 369-372.

Research output: Contribution to journalArticle

Deremer, David L. ; Katsanevas, Katerina ; Bradley, Amber ; Awan, Farrukh T. / Romiplostim resistance in secondary failure of platelet recovery. In: Journal of Oncology Pharmacy Practice. 2013 ; Vol. 19, No. 4. pp. 369-372.
@article{8cd3d78c6b59426f9c4583c18780b891,
title = "Romiplostim resistance in secondary failure of platelet recovery",
abstract = "Romiplostim, a thrombopoietin mimetic, is FDA approved for the treatment of thrombocytopenia in patients with refractory immune thrombocytopenia. Given the success of thrombopoietin agonists in the treatment of immune thrombocytopenia, data in other clinical settings are emerging. In the bone marrow transplant setting, secondary failure of platelet recovery and persistent thrombocytopenia are associated with increased mortality. In this case, romiplostim was attempted in a chronic lymphocytic leukemia patient who underwent a matched, unrelated donor, non-myeloablative stem cell transplant. This patient experienced profound thrombocytopenia despite dose escalation. Anti-thrombopoietin or anti-romiplostim antibodies were not detected by specific assays. Furthermore, the patient remains in disease remission with full chimerism. This case demonstrates that heavily pre-treated patients with limited bone marrow reserve may not respond to thrombopoietin agonists.",
keywords = "allogeneic stem cell transplant, chronic lymphocytic leukemia, romiplostim, Secondary failure of platelet recovery",
author = "Deremer, {David L.} and Katerina Katsanevas and Amber Bradley and Awan, {Farrukh T.}",
year = "2013",
month = "12",
day = "1",
doi = "10.1177/1078155212469640",
language = "English (US)",
volume = "19",
pages = "369--372",
journal = "Journal of Oncology Pharmacy Practice",
issn = "1078-1552",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Romiplostim resistance in secondary failure of platelet recovery

AU - Deremer, David L.

AU - Katsanevas, Katerina

AU - Bradley, Amber

AU - Awan, Farrukh T.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Romiplostim, a thrombopoietin mimetic, is FDA approved for the treatment of thrombocytopenia in patients with refractory immune thrombocytopenia. Given the success of thrombopoietin agonists in the treatment of immune thrombocytopenia, data in other clinical settings are emerging. In the bone marrow transplant setting, secondary failure of platelet recovery and persistent thrombocytopenia are associated with increased mortality. In this case, romiplostim was attempted in a chronic lymphocytic leukemia patient who underwent a matched, unrelated donor, non-myeloablative stem cell transplant. This patient experienced profound thrombocytopenia despite dose escalation. Anti-thrombopoietin or anti-romiplostim antibodies were not detected by specific assays. Furthermore, the patient remains in disease remission with full chimerism. This case demonstrates that heavily pre-treated patients with limited bone marrow reserve may not respond to thrombopoietin agonists.

AB - Romiplostim, a thrombopoietin mimetic, is FDA approved for the treatment of thrombocytopenia in patients with refractory immune thrombocytopenia. Given the success of thrombopoietin agonists in the treatment of immune thrombocytopenia, data in other clinical settings are emerging. In the bone marrow transplant setting, secondary failure of platelet recovery and persistent thrombocytopenia are associated with increased mortality. In this case, romiplostim was attempted in a chronic lymphocytic leukemia patient who underwent a matched, unrelated donor, non-myeloablative stem cell transplant. This patient experienced profound thrombocytopenia despite dose escalation. Anti-thrombopoietin or anti-romiplostim antibodies were not detected by specific assays. Furthermore, the patient remains in disease remission with full chimerism. This case demonstrates that heavily pre-treated patients with limited bone marrow reserve may not respond to thrombopoietin agonists.

KW - allogeneic stem cell transplant

KW - chronic lymphocytic leukemia

KW - romiplostim

KW - Secondary failure of platelet recovery

UR - http://www.scopus.com/inward/record.url?scp=84888113339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888113339&partnerID=8YFLogxK

U2 - 10.1177/1078155212469640

DO - 10.1177/1078155212469640

M3 - Article

C2 - 23292974

AN - SCOPUS:84888113339

VL - 19

SP - 369

EP - 372

JO - Journal of Oncology Pharmacy Practice

JF - Journal of Oncology Pharmacy Practice

SN - 1078-1552

IS - 4

ER -